Table 3.
Representativeness DQI 4: MS Clinical Course at Inclusion in CLARION
| MS Registry/Data Source | DQI 4; MS Clinical Course at Inclusion (% of Population) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RRMS | SPMS | PPMS | PRMS | Unknown | |||||||||
| Cladribine Cohort (N=2789) | Fingolimod Cohort (N=1964) | Total (N=4753) | Cladribine Cohort (N=2054) | Fingolimod Cohort (N=1754) | Total (N=3808) | Cladribine Cohort (N=2789) | Fingolimod Cohort (N=1964) | Total (N=4753) | Cladribine Cohort (N=2054) | Fingolimod Cohort (N=1754) | Total (N=3808) | Total (N=4753) | |
| Danish MS Registrya | 97.6 | 91.2 | 93.4 | 1.6 | 8.8 | 6.4 | 0.8 | 0.0 | 0.3 | NA | 0.0 | ||
| Finnish MS Registry | 96.9 | 94.3 | 95.7 | 2.6 | 5.7 | 4.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 |
| MSBase (multiple countries) | 84.1 | 93.4 | 89.0 | 6.1 | 2.4 | 4.1 | 1.1 | 0.3 | 0.7 | 0.9 | 0.1 | 0.5 | 5.7 |
| MSDS3D (Germany) | 97.2 | 100 | 98.0 | 2.8 | 0.0 | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Norwegian MS Registry and Biobankb | 94.7 | 94.8 | 94.7 | NA | 1.0 | 0.0 | 0.7 | NA | 4.6 | ||||
| Swedish MS Registrya | 94.6 | 94.8 | 94.7 | 4.2 | 3.9 | 4.1 | 1.1 | 1.3 | 1.2 | NA | 0.0 | ||
| Swiss MS Cohorta | 86.5 | 100 | 92.3 | 11.5 | 0.0 | 6.6 | 1.9 | 0.0 | 1.1 | NA | 0.0 | ||
| US Department of Defensec | NA | ||||||||||||
Notes: Cut-off date for most recent data quality indicators: November 1, 2022. aDanish and Swedish MS Registries, and the Swiss MS Cohort, do not have PRMS among possible MS course choices. bNorwegian MS Registry and Biobank did not report data on SPMS or PRMS. cUS Department of Defense did not report data concerning DQI 4.
Abbreviations: DMT, disease-modifying therapy; DQI, data quality indicator; MS, multiple sclerosis; MSBase, MS Database; MSDS3D, MS Management System 3D; NA, not applicable; PPMS, primary progressive MS; PRMS, primary relapsing MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS.